Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical
about
Concepts and clinical use of ultra-long basal insulinSafety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanCardiovascular effects of basal insulinsHypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.Medium-term effects of insulin degludec on patients with type 1 diabetes mellitus.Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia.Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice.Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitusBasal insulin analogues in the management of diabetes mellitus: What progress have we made?Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.A primer on concentrated insulins: what an internist should know.A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.Degludec: the new ultra-long insulin analogue.Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism.Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).The Future of Glucose Monitoring.Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study.Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study.Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements.Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes.Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes
P2860
Q26770354-FD757C39-1EA6-4650-926E-29A30A5F86A8Q26778763-AAB9A736-5491-4AFE-BDF7-621F14C41DBCQ26800249-BD969FA3-222F-45F5-8666-0BA2E0A48F04Q31046934-D42FA84A-B261-4F72-B23E-A3C96A624CF1Q31152059-9DE7EF02-377F-43F1-8F22-E1597FA9D24AQ31154873-C2CECB1F-5B4E-4FE4-8D2B-AAF8CF7C6F32Q33804815-65E65177-3853-4432-9224-939FA7BECDC6Q35549468-A917EC4E-042D-4DE2-98C3-B44692215E60Q35630711-4B916E2A-7B25-4039-AE91-69FB9291842BQ35921474-EE51ED59-542C-403D-945E-A81E523045D4Q36158944-02AF328E-F731-4594-A0F7-F077B31AF590Q36477634-245B8528-E91D-4BEF-8D36-3ACA32635DE4Q36554243-FCBC711F-3191-4330-8751-CD327AC88FF0Q37227385-F073EF1D-A12C-4815-BEA7-E4B31E667CFBQ37468435-487852EB-0D15-430A-9E6C-AED6DBA6E7ECQ38136581-3B5A2C35-AFE4-4C74-9E6F-37CE01FFC63EQ38241834-73C42F95-178E-42BD-BB63-96F2270A88C9Q38374620-586E0A0F-910A-4D72-8427-6DFFD64A41FFQ38470334-7DF0B950-D876-467E-81DB-AEEBCE316248Q38754210-21E98B8D-A6EA-41FE-8422-EEEB3B53672EQ41200024-EAE8D8C5-3F68-4B18-BC90-C3CA81DEC4B2Q41564970-DB2E9176-508B-4539-A1CA-E6119C9FA031Q42031194-A8F8218E-CE03-4729-BE89-FF75C9C4A4E5Q42329441-9F9D5A93-64FF-428E-8037-D885C31C3398Q43082355-1261C09D-F322-45AD-91CB-570675BCB1D4Q47871150-248C8F86-053C-4737-A708-265827435686Q47927613-B7A6707B-EE6A-4ABE-813A-4271DDF974B0Q48201978-F15A6301-D2CC-49D5-8196-B932114BB9CEQ48262568-E046A4DC-0754-4730-8C8F-EC9D469FFC5AQ51272007-E6E001DE-0742-421A-A49B-DDF8C2D131F2Q52606010-80B4D8FB-0DA0-467F-A8DB-0EFFA4ACC233Q52611423-FB9D4135-2630-4354-BB7C-3946B1E36D0EQ58712651-49B3381C-771D-4F9A-9CF9-6B09373B4F8F
P2860
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Insulin degludec improves glyc ...... sults of a randomized clinical
@ast
Insulin degludec improves glyc ...... sults of a randomized clinical
@en
Insulin degludec improves glyc ...... ulin aspart in Type 1 diabetes
@nl
type
label
Insulin degludec improves glyc ...... sults of a randomized clinical
@ast
Insulin degludec improves glyc ...... sults of a randomized clinical
@en
Insulin degludec improves glyc ...... ulin aspart in Type 1 diabetes
@nl
prefLabel
Insulin degludec improves glyc ...... sults of a randomized clinical
@ast
Insulin degludec improves glyc ...... sults of a randomized clinical
@en
Insulin degludec improves glyc ...... ulin aspart in Type 1 diabetes
@nl
P2093
P2860
P921
P356
P1433
P1476
Insulin degludec improves glyc ...... sults of a randomized clinical
@en
P2093
BEGIN® Basal-Bolus Type 1 trial investigators
C T Hansen
D L Russell-Jones
P2860
P304
P356
10.1111/DME.12243
P50
P577
2013-06-17T00:00:00Z